第一作者机构：[1]Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China[2]Capital Med Univ, Beijing TongRen Hosp, Dept Hematol, Beijing 100730, Peoples R China[3]Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China[4]Capital Med Univ, Beijing TongRen Hosp, Beijing 100730, Peoples R China[5]Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Dept Hematol, Shanghai 200011, Guangdong, Peoples R China[*1]Department of Hematology, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing TongRen Hospital, Beijing, 100730, China[*2]Department of Hematology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, Guangdong, China Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China
推荐引用方式(GB/T 7714)：
Liang Dan,Wei Cong,Zhang Xiaoting,et al.Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation[J].LEUKEMIA & LYMPHOMA.2021,62(10):2521-2525.doi:10.1080/10428194.2021.1919665.
APA：
Liang, Dan,Wei, Cong,Zhang, Xiaoting,Yang, Jilong,Zheng, Yaling...&Deng, Lan.(2021).Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.LEUKEMIA & LYMPHOMA,62,(10)
MLA：
Liang, Dan,et al."Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation".LEUKEMIA & LYMPHOMA 62..10(2021):2521-2525
